Photo of David Qian, Ph.D.

David Qian Ph.D.

  • (503) 312-5912
    • Associate Professor of Medicine School of Medicine
    • Cancer Biology Graduate Program School of Medicine

Dr. Qian’s laboratory studies the molecular and cellular mechanism of chemotherapy stress response and resistance and the epigenetics of hypoxia. The lab is investigating ways to target prostate cancer cells and angiogenesis with HDAC inhibitors. Dr. Qian also performs research in the Beer Lab.


  • Ph.D., The Johns Hopkins University School of Public Health, Baltimore Maryland 2002

Memberships and associations

  • American Association for Cancer Research


  • "The histone deacetylase inhibitor NVP-LAQ824 Inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584" Journal of Cancer Research September 15 2004
  • "The iroquois homeobox gene 5 is regulated by 1,25-dihydroxyvitamin D 3 in human prostate cancer and regulates apoptosis and the cell cycle in LNCaP prostate cancer cells" Clinical Cancer Research June 1 2008
  • "CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity" Prostate March 1 2010
  • "Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer" Journal of Cancer Research October 15 2010
  • "Genetic profiling to determine risk of relapse-free survival in high-risk localized prostate cancer" Clinical Cancer Research  2014
  • "Cigarette smoke and cancer" Journal of Oncology  2011
  • "Identification of a Potent Inhibitor of CREB-Mediated Gene Transcription with Efficacious in Vivo Anticancer Activity" Journal of Medicinal Chemistry June 25 2015
  • "The N-Myc down regulated gene1 (NDRG1) is a Rab4a effector involved in vesicular recycling of E-cadherin" PLoS One September 5 2007
  • "Prostate cancer - Associated gene expression alterations determined from needle biopsies" Clinical Cancer Research May 1 2009
  • "ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21 (Cancer Research (2010) 70, (3239-3248) DOI" Journal of Cancer Research June 1 2010
  • "In vivo imaging of retinoic acid receptor β2 transcriptional activation by the histone deacetylase inhibitor MS-275 in retinoid-resistant prostate cancer cells" Prostate June 15 2005
  • "ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21" Journal of Cancer Research April 15 2010
  • "Phase i study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours" British Journal of Cancer January 3 2012
  • "Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias" Clinical Cancer Research June 1 2004
  • "Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs" Cancer Chemotherapy and Pharmacology August 2007
  • "Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth" Proceedings of the National Academy of Sciences of the United States of America December 16 2008
  • "Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization" Proceedings of the National Academy of Sciences of the United States of America October 20 2009
  • "Malate dehydrogenase 2 confers docetaxel resistance via regulations of JNK signaling and oxidative metabolism" Prostate July 2013
  • "Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma" Molecular Cancer Therapeutics January 2007
  • "Functional regulation of hypoxia inducible factor-1α by SET9 lysine methyltransferase" Biochimica et Biophysica Acta - Molecular Cell Research May 1 2015
  • "Platelets take up the monoclonal antibody bevacizumab" Clinical Cancer Research September 15 2007
  • "Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models" Prostate August 1 2007
  • "Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells" Proceedings of the National Academy of Sciences of the United States of America February 17 2009
  • "A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma" Science Translational Medicine June 1 2011
  • "Identification of type 1 inosine monophosphate dehydrogenase as an antiangiogenic drug target" Journal of Medicinal Chemistry May 4 2006
  • "Identification of ABR-215050 as lead second generation quinoline-3- carboxamide anti-angiogenic agent for the treatment of prostate cancer" Prostate December 1 2006
  • "Blocking angiogenesis and histone deacetylases in prostate and breast cancer bearing mice" Cancer Biology and Therapy October 2004
  • "Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1α" Journal of Cancer Research September 1 2006
  • "HDAC4 protein regulates HIF1α protein lysine acetylation and cancer cell response to hypoxia" Journal of Biological Chemistry November 4 2011
  • "HIF1α protein stability is increased by acetylation at lysine 709" Journal of Biological Chemistry October 12 2012

Additional information

Edit profile